Indivior Reports Third Quarter 2026 Financial Results
Indivior reported record Q3 2026 results with total net revenue of $356 million, up 13% year-over-year, and record SUBLOCADE net revenue of $267 million, up 22%. Profitability inflected sharply: GAAP net income hit a record $137 million ($1.12 diluted EPS), non-GAAP net income $161 million ($1.32), and Adjusted EBITDA rose 76% YoY to $211 million on a 59% margin, up 2,100 basis points. The company reaffirmed its standalone FY2026 guidance (net revenue $1,295M-$1,365M, Adjusted EBITDA $700M-$740M) and confirmed the all-stock merger of equals with Supernus is on track to close November 2, 2026. Upon closing, the combined company will trade as Supernus, Inc.
Key figures
- Eps
- 1.12
- Revenue
- 356000000
- Guidance
- FY2026: net revenue $1,295M-$1,365M; SUBLOCADE net revenue $1,010M-$1,050M; non-GAAP operating expenses $430M-$450M; Adjusted EBITDA $700M-$740M (standalone, on track; guidance lapses at merger close)
- Revenue Yoy
- 13%
- Adjusted ebitda
- 211000000
- Gaap net income
- 137000000
- Net income margin
- 39%
- Nine month revenue
- 1016000000
- Adjusted ebitda yoy
- 76%
- Non gaap net income
- 161000000
- Cash and investments
- 332000000
- Sublocade net revenue
- 267000000
- Sublocade revenue yoy
- 22%
- Adjusted ebitda margin
- 59%
- Nine month revenue yoy
- 15%
- Patients prescribed sublocade
- 583000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.